D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

This trial is testing a combination of liver-directed treatments (D-TACE plus HAIC — chemotherapy delivered directly into the liver's blood supply) together with two systemic drugs (envafolimab, an immunotherapy, and lenvatinib, a targeted therapy) for people with bile duct cancer inside the liver (intrahepatic cholangiocarcinoma, or ICC) that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed by biopsy to have unresectable ICC - Your liver function is reasonably preserved (Child-Pugh A or B) - Your cancer has at least one measurable area on imaging - You have not received prior cancer treatment - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have had prior organ transplant or are planning one - You have active autoimmune disease - You have an active serious infection - You have severe bleeding tendency or are on full-dose blood thinners - You are pregnant or breastfeeding - You have a history of another cancer in the past 5 years Talk to your doctor to see if this trial is right for you.